Skip to main content
S&P 5007,704.81+1.80%DOW53,258.14+2.84%NASDAQ25,884.14+2.02%BTC$80,535.00+3.76%ETH$2,432.59+6.02%GOLD$4,078.30+3.50%OIL$88.78-7.61%
Smart Investors Daily
SID Premium
PA

NASDAQ · PAVM

PAVmed Inc.

Healthcare · Medical - Devices

$1.82

Up+$0.01 (+0.55%)

Updated Nov 4, 2026, 6:28 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
6.07M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$1.82 – $10.80
Volume
12.6K
Avg. volume
505.07K

Price performance · PAVM

PAVM price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

PAVM closed at $1.82 after 21 trading sessions, down 31.96% for the selected period.

Last close
$1.82
Period change
-31.96%
Period low
$1.82
Period high
$2.79
Daily close
View OHLC price history
PAVM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.8729$1.9799$1.82$1.8212.6K
Nov 2, 2026$1.8907$1.94$1.89$1.916.43K
Oct 30, 2026$1.995$2.08$1.95$1.956.62K
Oct 29, 2026$2.20$2.20$1.93$1.975.36K
Oct 28, 2026$2.12$2.25$2.08$2.0810.76K
Oct 27, 2026$2.205$2.26$2.10$2.148.79K
Oct 26, 2026$2.2239$2.2633$2.15$2.264.41K
Oct 23, 2026$2.28$2.30$1.84$2.1728.68K
Oct 22, 2026$2.285$2.285$2.04$2.0518.67K
Oct 21, 2026$2.27$2.27$2.085$2.0953.73K
Oct 20, 2026$2.26$2.37$2.135$2.236.13K
Oct 19, 2026$2.37$2.50$2.20$2.2530.1K
Oct 16, 2026$2.425$2.50$2.39$2.4112.59K
Oct 15, 2026$2.22$2.51$2.22$2.4258.43K
Oct 14, 2026$2.53$2.595$2.27$2.296.37K
Oct 13, 2026$2.61$2.81$2.58$2.643.24K
Oct 12, 2026$2.70$2.80$2.69$2.698.62K
Oct 9, 2026$2.58$2.89$2.58$2.7912.15K
Oct 8, 2026$2.76$2.76$2.655$2.694.14K
Oct 7, 2026$2.6977$2.84$2.60$2.7428.14K
Oct 6, 2026$2.65$2.93$2.65$2.67515.25K

Latest PAVM news

The latest Smart Investors Daily articles mentioning PAVM.

Stock researchCompany · Overview

PAVM research

Overview

Company profile and research snapshot.

Company profile

PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
PAVM recent ratings
DateFirmRatingTarget
Aug 27, 2026Ascendiant CapitalBuy—
Jun 8, 2026Ascendiant CapitalBuy—
Apr 9, 2026Ascendiant CapitalBuy—
Dec 10, 2025Ascendiant CapitalBuy—
Oct 6, 2025Ascendiant CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026

PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Friday, November 13, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition,

Yahoo · Oct 29, 2026

Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Thursday, November 12, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McG

Yahoo · Oct 22, 2026

Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has begun receiving payments from Medicare for its EsoGuard® Esophageal DNA Test. The Company also closed a $15.0 million private placement on October 21, 2026, for shares of its newly designated Series C Convertible Preferred Stock (the "Series C Preferred Stock") to existing long-term shareholde

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By